Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

NCT00077961 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: CAMPATH (alemtuzumab)

Sponsor

Genzyme, a Sanofi Company